Protagonist Therapeutics Inc (PTGX) USD0.00001

Sell:$41.35Buy:$49.00$1.24 (2.56%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$41.35
Buy:$49.00
Change:$1.24 (2.56%)
Market closed | Prices delayed by at least 15 minutes
Sell:$41.35
Buy:$49.00
Change:$1.24 (2.56%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Key people

Dinesh V. Patel
President, Chief Executive Officer, Director
Asif Ali
Chief Financial Officer, Executive Vice President
Suneel Gupta
Executive Vice President - Clinical Development
Arturo Molina
Chief Medical Officer
Harold E. Selick
Independent Chairman of the Board
Bryan M. Giraudo
Independent Director
Sarah A. O'Dowd
Independent Director
William D. Waddill
Independent Director
Lewis T. Williams
Independent Director
Click to see more

Key facts

  • EPIC
    PTGX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US74366E1029
  • Market cap
    $2.97bn
  • Employees
    126
  • Shares in issue
    61.38m
  • Exchange
    NASDAQ
  • Index
    S&P 600 Small Cap, TR Equity United States Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.